Direct synthesis of 5- and 6-substituted 2-aminopyrimidines as potential non-natural nucleobase analogues

K. Radhakrishnan, Namita Sharma and Lal Mohan Kundu*
Department of Chemistry, Indian Institute of Technology Guwahati, North Guwahati, 781039, Assam, India. E-mail: lmkundu@iitg.ernet.in; Fax: +91-3612582349; Tel: +91-3612582326

Received 10th January 2014 , Accepted 14th March 2014

First published on 14th March 2014


Abstract

A series of 2-aminopyrimidine derivatives, substituted at 5- and 6-positions, were synthesized. The reaction was carried out in a single step by treatment of the corresponding β-ketoester or β-aldehydoester with guanidine hydrochloride in the presence of K2CO3, in a microwave-assisted method without the requirement of solvent. A unique 1[thin space (1/6-em)]:[thin space (1/6-em)]1 co-crystal structure was obtained which shows that a 6-phenyl-2-aminopyrimidinone forms a strong nucleobase-pair with cytosine, involving three hydrogen bonds. The base-pair was found to be as strong as that of natural guanine:cytosine (G:C), signifying the potential application of the synthesized derivatives. Additionally, we also report a second co-crystal involving 5-isopropyl-6-methyl-2-aminopyrimidinone and cytosine in a 1[thin space (1/6-em)]:[thin space (1/6-em)]1 ratio, which also shows strong base-pairing properties.


Heterocyclic compounds, such as pyrimidines, have found a wide range of applications in the pharmaceutical industry as anti-bacterial, anti-viral and anti-tumor agents, as well as their applications as artificial base-pairs.1–5 Biological activities of such heterocycles are largely due to their structural resemblance to the nucleobases or coenzymes, enabling them to act as potential inhibitors.

A substantial number of 2-aminopyrimidine compounds were synthesized and many derivatives have been found to be clinically active molecules that exhibit cytotoxic, antibacterial and other kinds of inhibition properties.6–9 Developing low-cost and efficient synthetic methodologies are important for the production of such compounds. Most commonly, 2-aminopyrimidine derivatives are synthesized following two procedures: (a) through reaction of substituted β-ketoester with guanidine.10–12 The process requires long reflux and use of substantial amount of concentrated base as well as organic solvents; (b) three-component Biginelli reaction involving a β-ketoester, an aldehyde and guanidine, in presence of strong base and organic solvent.13–15 In this article, we describe a one-pot synthesis of a series of 2-amino-4-pyrimidinones, a class of 2-aminopyrimidines or commonly known as isocytosines, in a microwave-directed method in solvent free condition. The reaction proceeds smoothly in presence of a mild base (K2CO3). The synthesized isocytosines vary in their substitutions at C-5 and C-6 positions (Scheme 1). Although microwave-assisted reactions have been applied to synthesize pyrimidines and uracil derivatives, to the best of our knowledge, it was never reported for the synthesis of 2-aminopyrimidine compounds.16–20


image file: c4ra00249k-s1.tif
Scheme 1 Schematic presentation for the synthesis of 2-amino-4-pyrimidinones. R, R1 and R2 are given in Table 1.

Isocytosine is an isomer of cytosine which has tendency to form reverse Watson–Crick base pair with guanine leading to formation of parallel-stranded DNA helix.21–23 Sugiyama et al. have demonstrated the use of oligonucleotides containing isocytosine to selectively recognize guanine as well as isoguanine, a potential oxidative lesion in DNA.24 Moreover, C-glycosidic isocytidine was employed as triplex forming oligonucleotides whereas N-glycosidic isocytosine was reported for diagnostic assay of branched DNA.25–27 Isocytosine based self-assembled supramolecular polymers have also been used for the development of smart materials.28 Apart from being used as a probe nucleobase, isocytosine and their derivatives were widely studied as inhibitors and pharmaceutically important molecules. Development of such isocytosine derivatives with varying stereo-electronic properties, through convenient methods and studying the crystal structures, therefore, will be highly relevant for potential biological as well as pharmaceutical applications.

Compounds 1–15 were synthesized in a closed vessel CEM Discover LabMate microwave reactor in absence of solvent, as shown in Table 1. In general, 2 mmol of the substrate ester was taken with 4 mmol of guanidine hydrochloride along with 2 mmol of K2CO3 in a closed reaction vessel. The reaction attained completion upon irradiation for about 10 minutes and the temperature of the reaction vessel was kept at around 140 °C (see ESI). In order to show diversity, a wide range of β-ketoesters (1–12), β-amidoester (13) and β-aldehydoester (14) were used as substrates, leading to formation of a variety of 2-amino-4-pyrimidinones, including a functionalized derivative (15), in a single step. The reaction occurs when the solid guanidine hydrochloride melts into the liquid substrate ester inside the microwave reactor. The reaction did not proceed in absence K2CO3, even at higher temperature. To our understanding, this mild base primarily acts as a scavenger of hydrochloric acid, present in the guanidine salt. The yields of the reactions were increased when two equivalents of guanidine hydrochloride was used instead of stoichiometric ratio. It is noteworthy from Table 1 that the reactivity of the substituted β-ketoesters 6–11 were found to be lowered, presumably due to increased steric crowding in the transition state. This can be evident from the mechanism proposed earlier by our group, where we had trapped the partially condensed intermediate.19 Use of organic bases such as, DBU and triethylamine, in place of K2CO3, exhibited very poor yield.

Table 1 Synthesis of various 2-amino-4-pyrimidinone derivatives (1–15) in a microwave-assisted method. All irradiations were performed at 140 °C for 10 min, in a closed vessel
S. no. Substrate (1a–8a) Product (1–8) Yield% S. no. Substrate (9a–15a) Product (9–15) Yield%
1 image file: c4ra00249k-u1.tif image file: c4ra00249k-u9.tif 85 9 image file: c4ra00249k-u17.tif image file: c4ra00249k-u24.tif 72
2 image file: c4ra00249k-u2.tif image file: c4ra00249k-u10.tif 82 10 image file: c4ra00249k-u18.tif image file: c4ra00249k-u25.tif 60
3 image file: c4ra00249k-u3.tif image file: c4ra00249k-u11.tif 84 11 image file: c4ra00249k-u19.tif image file: c4ra00249k-u26.tif 61
4 image file: c4ra00249k-u4.tif image file: c4ra00249k-u12.tif 79 12 image file: c4ra00249k-u20.tif image file: c4ra00249k-u27.tif 86
5 image file: c4ra00249k-u5.tif image file: c4ra00249k-u13.tif 82 13 image file: c4ra00249k-u21.tif image file: c4ra00249k-u28.tif 70
6 image file: c4ra00249k-u6.tif image file: c4ra00249k-u14.tif 76 14 image file: c4ra00249k-u22.tif image file: c4ra00249k-u29.tif 80
7 image file: c4ra00249k-u7.tif image file: c4ra00249k-u15.tif 73 15 image file: c4ra00249k-u23.tif image file: c4ra00249k-u30.tif 70
8 image file: c4ra00249k-u8.tif image file: c4ra00249k-u16.tif 67  


Another important aspect of this article is to analyse the co-crystal structures of the synthesized isocytosine derivatives with free nucleobase cytosine. Evidence of such co-crystals involving modified nucleobases is rare.29–31 We have obtained two co-crystals, 6-phenylisocytosine (5):cytosine and 5-isopropyl-6-methylisocytosine (6):cytosine, both in 1[thin space (1/6-em)]:[thin space (1/6-em)]1 ratio.32 Fig. 1 depicts the ORTEP diagrams of the co-crystals obtained from methanol–water (2[thin space (1/6-em)]:[thin space (1/6-em)]1 v/v). It can be observed from the ORTEP diagram that the co-crystal of compound 5 with cytosine shows remarkably strong base-pair formation involving three hydrogen bonds, similar to that of natural G:C base pair. The strength of the H-bonds of the co-crystal were found to be as strong as that of Watson–Crick G:C base pair.33 Compound 5, therefore, could have potential applications as non-natural nucleotide and as oligonucleotide probe to selectively recognize cytosine in DNA. The co-crystal structure of compound 6 with cytosine, on the other hand, show relatively weaker H-bonds as compared to natural G:C base-pair.


image file: c4ra00249k-f1.tif
Fig. 1 ORTEP diagrams of the co-crystals. 1A represents the ORTEP diagram for 6-phenylisocytosine (5):cytosine. H-bond distance: O1⋯N6 (2.81 Å), N1⋯N4 (2.87 Å), O3⋯N2 (2.90 Å). 1B represents the ORTEP diagram for 5-isopropyl-6-methylisocytosine (6):cytosine. H-bond distance: O1⋯N6 (2.93 Å), N2⋯N5 (2.95 Å) and N1⋯O2 (2.92 Å).

The supramolecular self-assembly of the co-crystals were also studied. The 6-phenylisocytosine (5):cytosine co-crystal shows a helix-type molecular architecture, as demonstrated in Fig. 2. On the other hand, the co-crystal of 5-isopropyl-6-methylisocytosine (6):cytosine, presents a unique hexagonal self-assembled structure connected by water molecules, creating a rectangular void space. The beauty of such crystals is that, by varying the substitution at 5- and 6-position of 2-amino-4-pyrimidinones, shape of the molecular architecture could be controlled.


image file: c4ra00249k-f2.tif
Fig. 2 Supramolecular architecture of the co-crystals. Left: co-crystal of compound 5 with cytosine. Right: co-crystal of compound 6 with cytosine. Red dots represent water molecules.

Conclusions

In this communication we have demonstrated a one-pot, microwave-directed methodology for the synthesis of biologically active 2-amino-4-pyrimidinones, a class of 2-aminopyrimidines. The high-yield reactions were performed in presence of mild base (K2CO3) without any solvent and were completed in a very short period of time (10 min). In order to study potential utilities of the synthesized compounds as artificial nucleobase-pairs, we have isolated co-crystals which show strong pairing properties with cytosine, as strong as that of natural G:C base-pair. Such modified nucleobase analogues could have potential applications for biomolecular recognition, apart from their pharmaceutical uses.

Acknowledgements

We would like to acknowledge DST-SERB (Grant no. SR/FT/SC-27/2011), New Delhi, India, for providing the laboratory equipments and financial assistance. We thank CSIR (New Delhi, India, grant no. 02(0017)/11/EMR-II) for financial support. We also acknowledge CIF, IIT Guwahati, for recording the NMR spectra.

Notes and references

  1. D. B. Longley, D. P. Harkin and P. G. Johnston, Nat. Rev. Cancer, 2003, 3, 330 CrossRef CAS PubMed.
  2. K. Gharehbaghi, W. Zhen, M. F. Szekeres, T. Szekeres and H. N. Jayram, Life Sci., 1999, 64, 103 CrossRef CAS PubMed.
  3. K. Eger, E. M. Klünder and M. Schmidt, J. Med. Chem., 1994, 37, 3057 CrossRef CAS PubMed.
  4. M. Loeffler, L. D. Fairbanks, E. Zameitat, A. M. Marinaki and H. A. Simmonds, Trends Mol. Med., 2005, 11, 430 CrossRef CAS PubMed.
  5. H. Liu, J. Gao, L. Maynard, Y. D. Saito and E. T. Kool, J. Am. Chem. Soc., 2004, 126, 1102 CrossRef CAS PubMed.
  6. L. M. Beauchamp, B. L. Serling, J. E. Kelsey, K. K. Biron, P. Collins, J. Selway, J.-C. Lin and H. J. Schaeffer, J. Med. Chem., 1988, 31, 144 CrossRef CAS PubMed.
  7. J. H. Burchenal, K. Ciovacco, K. Kalaher, T. O'Toole, R. Kiefner, M. D. Dowling, C. K. Chu, K. A. Watanabe and J. J. Fox, J. Cancer Res., 1976, 36, 1520 CAS.
  8. S. Khanna, S. Burudkar, K. Bajaj, P. Shah, A. Keche, U. Ghosh, A. Desai, A. Srivastava, A. K. Almeida, N. J. Deshmukh, A. Dixit, M. K. Brahma, U. Bahirat, L. Doshi, K. V. S. Nemmani, P. Tannu, A. Damre, C. B. Rao, R. Sharma and H. Sivaramakrishnan, Bioorg. Med. Chem. Lett., 2012, 22, 7543 CrossRef CAS PubMed.
  9. C. B. Rao, A. K. Almeida, K. V. Katkar, S. Khanna, U. Ghosh, A. Keche, P. Shah, A. Srivastava, V. Korde, K. V. S. Nemmani, N. J. Deshmukh, A. Dixit, M. K. Brahma, U. Bahirat, L. Doshi, R. Sharma and H. Sivaramakrishnan, Bioorg. Med. Chem., 2012, 20, 2930 CrossRef PubMed.
  10. P. S. Shirude, B. Paul, N. R. Choudhury, C. Kedari, B. Bandodkar and B. G. Ugarkar, ACS Med. Chem. Lett., 2012, 3, 736 CrossRef CAS PubMed.
  11. F. H. Beijer, R. P. Sijbesma, H. Kooijiman, A. L. Spek and E. W. Meijer, J. Am. Chem. Soc., 1998, 120, 6761 CrossRef CAS.
  12. W. Wierenga, H. I. Skulnick, D. A. Stringfellow, S. D. Weed, H. E. Renis and E. E. Eidson, J. Med. Chem., 1980, 23, 237 CrossRef CAS PubMed.
  13. E. E. Wyatt, W. R. J. D. Galloway, G. L. Thomas, M. Welch, O. Loiseleur, A. T. Plowright and D. R. Spring, Chem. Commun., 2008, 4962 RSC.
  14. B. Ahmed, R. A. Khan, Habibullah and M. Keshari, Tetrahedron Lett., 2009, 50, 2889 CrossRef CAS.
  15. M. B. Deshmukh, S. M. Salunkhe, D. R. Patil and P. V. Anbhule, Eur. J. Med. Chem., 2009, 44, 2651 CrossRef CAS PubMed.
  16. A. Stadler and C. O. Kappe, J. Comb. Chem., 2001, 3, 624 CrossRef CAS PubMed.
  17. M. Matloobi and C. O. Kappe, J. Comb. Chem., 2007, 9, 275 CrossRef CAS PubMed.
  18. O. K. Ahmed, M. D. Hill and M. Movassaghi, J. Org. Chem., 2009, 74, 8460 CrossRef PubMed.
  19. L. N. Burgula, K. Radhakrishnan and L. M. Kundu, Tetrahedron Lett., 2012, 53, 2639 CrossRef CAS.
  20. M. S. Digani, S. Bag, R. Bairwa, N. R. Tawari and S. F. Queener, J. Heterocycl. Chem., 2010, 47, 558 Search PubMed.
  21. K. P. Rice, J. C. Chaput, M. M. Cox and C. Switzer, Biochemistry, 2000, 39, 10177 CrossRef CAS PubMed.
  22. C. Roberts, R. Bandaru and C. Switzer, J. Am. Chem. Soc., 1997, 119, 4640 CrossRef CAS.
  23. C. Roberts, R. Bandaru and C. Switzer, Tetrahedron Lett., 1995, 36, 3601 CrossRef CAS.
  24. X.-L. Yang, H. Sugiyama, S. Ikeda, I. Saito and A. H.-J. Wang, Biophys. J., 1998, 75, 1163 CrossRef CAS PubMed.
  25. A. Ono, P. O. P. Ts'o and L.-S. Kan, J. Am. Chem. Soc., 1991, 113, 4032 CrossRef CAS.
  26. A. Mayer, A. Haeberli and C. J. Leumann, Org. Biomol. Chem., 2005, 3, 1653 CAS.
  27. K. W. Wellington, H. C. Ooi and S. A. Benner, Nucleosides, Nucleotides Nucleic Acids, 2009, 28, 275 CAS.
  28. T. Ware, K. Hearon, A. Lonnecker, K. L. Wooley, D. J. Maitland and W. Voit, Macromolecules, 2012, 45, 1062 CrossRef CAS PubMed.
  29. D. Gupta, M. Roitzsch and B. Lippert, Chem. – Eur. J., 2005, 11, 6643 CrossRef CAS PubMed.
  30. K. Radhakrishnan, L. N. Burgula and L. M. Kundu, RSC Adv., 2013, 3, 7282 RSC.
  31. S. Chandrasekhar, T. R. V. Naik, S. K. Nayak and T. N. G. Row, Bioorg. Med. Chem. Lett., 2010, 20, 3530 CrossRef CAS PubMed.
  32. Co-crystal data for compound 5:cytosine complex: CCDC # 980518. Formula: C10H9N3O/C4H5N3O. Temperature (K): 296 (2). Monoclinic, P21/c. a = 12.4798(6) Å, b = 6.8611(5) Å, c = 17.0339(10) Å. α = 90.00°, β = 95.021(5)°, γ = 90.00°. Unit cell volume = 1452.94(15) Å. Z = 4. μ = 0.097 mm−1, ρ (calc.) = 1.364 g cm−3, Mo Kα radiation, R1 = 0.0501, R1,all data = 0.0678, wR (F2) = 0.0856, wR (F2)all data = 0.0935. Co-crystal data for compound 6:cytosine complex: CCDC # 980516. Formula: C8H13N3O/C4H5N3O·H2O. Temperature (K): 296 (2). Monoclinic, P21/n. a = 15.5249(9) Å, b = 5.5769(3) Å, c = 18.7323(11) Å. α = 90.00°, β = 112.714(3)°, γ = 90.00°. Unit cell volume = 1496.07(15) Å. Z = 4. μ = 0.098 mm−1, ρ (calc.) = 1.316 g cm−3, Mo Kα radiation, R1 = 0.0405, R1,all data = 0.0528, wR (F2) = 0.1109, wR (F2)all data = 0.1209.
  33. K. Brameld, S. Dasgupta and W. A. Goddard III, J. Phys. Chem. B, 1997, 101, 4851 CrossRef CAS.

Footnote

Electronic supplementary information (ESI) available. CCDC 980516–980518. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4ra00249k

This journal is © The Royal Society of Chemistry 2014
Click here to see how this site uses Cookies. View our privacy policy here.